|
|
|
|
LEADER |
00000cam a2200000Ia 4500 |
001 |
EBSCO_ocn959151059 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
160924s2016 nyu o 001 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCO
|d OCLCQ
|d N$T
|d OCLCQ
|d OCLCF
|d SNK
|d DKU
|d AUW
|d IGB
|d D6H
|d VTS
|d AGLDB
|d AU@
|d OCLCO
|d G3B
|d OCLCA
|d S8J
|d S9I
|d STF
|d OCLCQ
|d OCLCO
|d OCLCQ
|
020 |
|
|
|a 9781634840170
|q (electronic bk.)
|
020 |
|
|
|a 1634840178
|q (electronic bk.)
|
020 |
|
|
|z 9781634840170
|
020 |
|
|
|z 1634840178
|
029 |
1 |
|
|a AU@
|b 000062422201
|
035 |
|
|
|a (OCoLC)959151059
|
050 |
|
4 |
|a QP572.S4
|
072 |
|
7 |
|a MED
|x 075000
|2 bisacsh
|
072 |
|
7 |
|a SCI
|x 036000
|2 bisacsh
|
082 |
0 |
4 |
|a 612.6
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Anti-Müllerian hormone :
|b biology, role in ovarian function and clinical significance /
|c David B. Seifer and Reshef Tal, editors.
|
260 |
|
|
|a New York :
|b Nova Science Publishers, Inc.,
|c 2016.
|
300 |
|
|
|a 1 online resource (357 pages).
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a data file
|2 rda
|
490 |
1 |
|
|a Obstetrics and Gynecology Advances
|
588 |
0 |
|
|a Print version record.
|
500 |
|
|
|a Includes index.
|
505 |
0 |
|
|a ANTI-MÜLLERIAN HORMONE BIOLOGY, ROLE IN OVARIAN FUNCTION AND CLINICAL SIGNIFICANCE; ANTI-MÜLLERIAN HORMONE BIOLOGY, ROLE IN OVARIAN FUNCTION AND CLINICAL SIGNIFICANCE; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; INTRODUCTION; REFERENCES; Chapter 1: THE RELEVANCE OF AMH TO HUMAN REPRODUCTIVE BIOLOGY AND MEDICINE; ABSTRACT; INTRODUCTION; REFERENCES; Chapter 2: BASIC BIOLOGY OF AMH: STRUCTURE, SIGNALING PATHWAYS, AND ROLE IN NORMAL FOLLICULOGENESIS; ABSTRACT; INTRODUCTION; STRUCTURE AND PROCESSING OF THE AMH PROTEIN; AMH SIGNALING PATHWAY.
|
505 |
8 |
|
|a EXPRESSION OF AMH AND ITS RECEPTORS IN THE OVARYROLE OF AMH IN OVARIAN PHYSIOLOGY; Inhibition of Primordial Follicle Recruitment; Inhibition of FSH Responsiveness; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 3: STUDIES ON ANTI-MÜLLERIAN HORMONE PRODUCTION, ACTION, AND REGULATION IN THE PRIMATE OVARY: INSIGHT INTO HUMAN FOLLICULOGENESIS; ABSTRACT; INTRODUCTION; AMH PRODUCTION IN THE PRIMATE OVARY; AMH ACTIONS IN THE PRIMATE OVARY; AMH Actions in Preantral Follicles; AMH Actions in Antral Follicles; AMH REGULATION IN THE PRIMATE OVARY; Factors Regulating AMH.
|
505 |
8 |
|
|a AMH-Regulated FactorsAMH AS A MARKER FOR PRIMATE FOLLICULAR DEVELOPMENT IN VITRO; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 4: OPTIONS FOR CHOOSING DIFFERENT AMH ASSAYS; ABSTRACT; INTRODUCTION; The Sources of AMH and Normal Ranges; Assay Matters; HISTORY OF AMH ASSAY DEVELOPMENT; Commercialisation of the AMH Assays; The Gen II Assay and Problems Following its Introduction; The International Standard for AMH; Assay Sensitivity and Performance; Practicalities of Batch and Automated Assays; Uses of Assays for Experimental and Routine Purposes; Timeliness and Efficiency.
|
505 |
8 |
|
|a Studies at the Extremes of Normal ConcentrationsNormal Ranges and Reporting; Implications for Future Applications; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 5: THE VALUE OF NORMATIVE DATA ON AMH IN WOMEN; ABSTRACT; INTRODUCTION; AMH throughout Life; AMH Postnatal and During Puberty; Menstrual Cycle Variation; Circadian Rhythm in AMH; Intra-Follicular AMH Levels; AMH and Fecundability; Pregnancy; Perimenopausal Levels; Assay Issues; Areas for Further Research; REFERENCES; Chapter 6: ANTI-MÜLLERIAN HORMONE AND THE PREDICTION OF AGE AT NATURAL MENOPAUSE; ABSTRACT.
|
505 |
8 |
|
|a 1. INTRODUCTION2. OVERVIEW OF EXISTING EVIDENCE; 3. SUMMARY OF EXISTING EVIDENCE; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 7: USING AMH FOR DETERMINING A STRATIFIED GONADOTROPIN DOSING REGIME NFOR IVF/ICSI AND OPTIMIZING OUTCOMES; ABSTRACT; 1. INTRODUCTION; 2. BIOMARKER EVALUATION FOR OPTIMIZING GONADOTROPIN DOSING; 2.1. Predictive Value of AMH -- Data from Randomized Controlled Trials; 3. CLINICAL APPLICATION OF STRATIFIED MEDICINE -- THE FE 999049 (FOLLITROPIN DELTA) CASE; 3.1. AMH Incorporated in Phase 2 Development; 3.2. Modeling and Simulation.
|
500 |
|
|
|a 3.2.1. Pharmacokinetic (PK) Model Step.
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Hormones, Sex.
|
650 |
|
2 |
|a Gonadal Hormones
|
650 |
|
2 |
|a Gonadal Steroid Hormones
|
650 |
|
6 |
|a Hormones sexuelles.
|
650 |
|
7 |
|a MEDICAL
|x Physiology.
|2 bisacsh
|
650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Human Anatomy & Physiology.
|2 bisacsh
|
650 |
|
7 |
|a Hormones, Sex.
|2 fast
|0 (OCoLC)fst00960232
|
700 |
1 |
|
|a Seifer, David B.,
|d 1955-
|
700 |
1 |
|
|a Tal, Reshef.
|
776 |
0 |
8 |
|i Print version:
|t Anti-Müllerian hormone.
|d New York : Nova Science Publishers, Inc., 2016
|z 9781634840125
|
830 |
|
0 |
|a Obstetrics and gynecology advances.
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1345551
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4691135
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 1345551
|
994 |
|
|
|a 92
|b IZTAP
|